Here’s the ribbon breaking ceremony picture. Let’s all hope this is a success and hopefully some new technology will enter the picture as well with remote batch monitoring of products manufactured in China and other locations in the world. There is only so much an in person visit can cover, so perhaps some nice remote monitoring can be set up to not only keep daily track, but serve to subsidize in person visits to the factories. Data management can do it as a less expensive cost once set up.
We meet remotely and have have web meetings today so why not some web monitoring of the factories where product is made, and for that matter the same could be set up for all our factories here too as nobody is beyond fault these days. When chemical content is reported back by data systems, an alert to both the FDA and the factory would be initiated. As we all know there should already be some quality controls somewhere along the line in place and by have an automated data function provide some intelligence, it would also serve to make the in house visits by members of the FDA more meaningful as well.
We have the technology and the question I am guessing at this point is whether or not plans will be made to institute quality control for food and drug products manufactured around the world.
When it comes to financial data, such as Wall Street, no barriers were barred there as far as having reporting functions and the algorithms to produce desired results, so to do something healthy with technology that will benefit all would truly be once welcome addition to our global economy and food and drug safety programs. I am growing very tired of having to post tainted food and drug products that a little technology could have possibly served to avert the entire situations when technology and reporting functions with business intelligence stand to make us not only better consumers, but better producers as well. In the related articles below there are also some references to clinical trials and drug developments between partners here in the US and those in China as in the one example, data from Chinese R and D scientists were immediately accepted by the FDA, one item that was a bit of a surprise for all. BD
（From L to R) Mike Leavitt, US Health and Human Services Secretary, Shao Mingli, head of the State Food and Drug Administration (SFDA), Andrew von Eschenbach, FDA Commissioner and the US Ambassador to China Clark T. Randt Jr. cut the ribbon at the opening ceremony of the FDA Beijing office, November 19, 2008. The US FDA will open three offices in Beijing, Guangzhou and Shanghai this week to help ensure export safety while China is also preparing to station offices in the US. [Asianewsphoto]
Hat Tip: Pharmagossip
0 comments :
Post a Comment